Theralase Technologies Inc. V.TLT

Anticancer Photodynamic Therapy

[Gustoes]

https://hal.archives-ouvertes.fr/hal-02492644/document


Polymetallic Complexes for Applications as Photosensitizers in Anticancer Photodynamic Therapy


Three other very promising PDT PS candidates containing metals are in clinical trials, namely Purlytin (Figure 2: 3), TLD1433 (4) and LuTex (5, also called Lutrin or Antrin).

The experiments revealed a mean residence time (MRT) of 85.4h in the plasma, respectively 38.4h in the tumor and a half-life time (t1/2) of 58.0h in the plasma and 26.9h in the tumor.[52] ICP-MS experiments confirmed the accumulation of 8 in the liver and the kidneys. The absence of measurable Ru in the brain tissue suggests that 8 seems unable to cross the blood-brain barrier (BBB).[52] The high (photo)chemical stability, low tendency for photobleaching, low toxicity, as well as their easy tunable solubility behavior make Ru(II) polypyridyl complexes one of the most extensively studied families of PDT PSs.[1,1,3,64–67] As a flagship compound, TLD1433 (see introduction, compound 4) has just entered phase II clinical trials.[3] It is therefore not surprising that such an important compound class also contains several polynuclear species. As already shown before, the combination of PDT PSs with platinumbased anti-cancer drugs might have many beneficial effects.

Conclusion Metal complexes are currently being highly investigated as alternative PDT PSs with great success as demonstrated with TOOKAD soluble and TLD1433 discussed in this review.